Payment overview · 2025
General Payments
$30,380.01
53 reported records · 12 companies
Healthcare provider profile · identity verified
Jared S Kramer, MD
Allopathic & Osteopathic Physicians|Family Medicine · ST PAUL, NE · NPI 1134105463
Verified facts
What the public records show
CMS Open Payments records show Jared S Kramer, MD received $30,380.01 in general payments during 2025 across 53 reported records.
Novo Nordisk Inc accounted for 97.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Farxiga, Ozempic, Rybelsus.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29,693.24 | 97.7% | 31 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $292.94 | 1.0% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $141.33 | 0.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $65.34 | 0.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.56 | 0.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.14 | 0.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.89 | 0.1% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.61 | 0.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.56 | 0.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.91 | 0.1% | 1 | 2025 |
| BioWound Solutions, Inc. | Unresolved — no canonical attribution shown | $14.96 | 0.1% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.53 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $26,172.38 | 9 |
| Travel and Lodging | $2,720.02 | 9 |
| Food and Beverage | $1,487.61 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29,693.24 | 31 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $244.97 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $241.68 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $193.71 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $141.33 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $77.60 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $65.34 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.56 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.56 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.56 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.14 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.89 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| bio-ConneKt Normalized: bio connekt |
Device | BioWound Solutions, Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 46 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 136 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
136 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
46 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
168 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 353 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 333 | 77 |
| Furosemide | Furosemide | 298 | 66 |
| Celecoxib | Celecoxib | 283 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 62 |
| Lisinopril | Lisinopril | 207 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 36 |
| Gabapentin | Gabapentin | 200 | 42 |
| Omeprazole | Omeprazole | 186 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 39 |
| Eliquis | Apixaban | 168 | 19 |
| Potassium Chloride | Potassium Chloride | 165 | 33 |
| Montelukast Sodium | Montelukast Sodium | 158 | 37 |
| Ozempic | Semaglutide | 136 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 34 |
| Trazodone Hcl | Trazodone Hcl | 135 | 24 |
| Prednisone | Prednisone | 129 | 69 |
| Tramadol Hcl | Tramadol Hcl | 129 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 121 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 29 |
| Famotidine | Famotidine | 107 | 27 |
| Losartan Potassium | Losartan Potassium | 104 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 83 | 16 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 80 | 12 |
| Donepezil Hcl | Donepezil Hcl | 75 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 17 |
| Valsartan | Valsartan | 68 | 18 |
| Simvastatin | Simvastatin | 63 | 13 |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Meloxicam | Meloxicam | 61 | 20 |
| Metformin Hcl | Metformin Hcl | 59 | 14 |
| Alprazolam | Alprazolam | 57 | suppressed |
| Jardiance | Empagliflozin | 56 | 12 |
| Bupropion Xl | Bupropion Hcl | 53 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 14 |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 11 |
| Allopurinol | Allopurinol | 50 | 11 |
| Baclofen | Baclofen | 50 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 46 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 13 |
| Metformin Hcl Er | Metformin Hcl | 42 | 11 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Cefdinir | Cefdinir | 39 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Ramipril | Ramipril | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 12 |
| Azithromycin | Azithromycin | 32 | 24 |
| Diltiazem 24hr Er | Diltiazem Hcl | 32 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 31 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Lorazepam | Lorazepam | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 15 |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 11 |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 16 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30,380.01 · 53 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, DALVANCE, EVENITY, FARXIGA, Kerendia, NEXLETOL, Ozempic, PREVNAR 20, Rybelsus, SPRAVATO, VOQUEZNA, Veozah, YUPELRI, bio-ConneKt | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error